# US 2017/0362626 A1 · Methods for making proteins containing free cysteine residues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362626 A1
- Document ID: US20170362626A1
- Status: Published application
- Kind: A1
- Application number: 15/414,020
- Filed: 2017-01-24
- Published: 2017-12-21
- Earliest claimed: 1999-01-14
- Assignees: Bolder Biotechnology, Inc.
- Applicants: Bolder Biotechnology, Inc.
- Inventors: George N. Cox; Daniel H. Doherty; Mary S. Rosendahl
- Web page: https://patentgrep.com/patent/US20170362626A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C07K 1/1133: {by redox-reactions involving cystein/cystin side chains}
- C07K 14/505: Erythropoietin [EPO]
- C07K 14/56: IFN-alpha
- C07K 14/61: Growth hormone [GH], i.e. somatotropin
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- C12P 21/005: {Glycopeptides, glycoproteins}
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

An isolated, disulfide-linked growth hormone protein dimer comprising two growth hormone protein monomers, wherein each growth hormone protein monomer in the dimer comprises at least one added cysteine residue, wherein at least one of the added cysteine residues participates in a disulfide bond joining the two growth hormone protein monomers together in the dimer, and wherein the protein dimer stimulates proliferation of a cell line that proliferates in response to growth hormone.

### Claim 33 (depends on 32)

The isolated growth hormone protein of claim 32, where the growth hormone protein is human Growth Hormone.

### Claim 34 (depends on 33)

The isolated human Growth Hormone protein of claim 33, wherein said human Growth Hormone protein comprises a cysteine residue added preceding the F1 amino acid of the mature human Growth Hormone protein.

### Claim 35 (depends on 33)

The isolated human Growth Hormone protein of claim 33, where said human Growth Hormone protein comprises a cysteine residue added following the terminal F191 amino acid of the mature human Growth Hormone protein.

### Claim 36 (depends on 33)

The isolated human Growth Hormone protein of claim 33, where said human Growth Hormone protein comprises a cysteine residue substituted for at least one amino acid selected from the group consisting of P2, T3, P5, A34, K38, Q40, S43, S55, S57, A98, N99, S100, L101, V102, Y103, A105, S132, P133, R134, T135, Q137, K140, Q141, Y143, S144, D147, T148, N149, E186, and G187.

### Claim 37 (depends on 33)

The isolated human Growth Hormone protein of claim 33, where said human Growth Hormone protein comprises a cysteine residue substituted for T3.

### Claim 38 (depends on 33)

The isolated human Growth Hormone protein of claim 33, where said human Growth Hormone protein comprises a cysteine residue substituted for A105.

### Claim 39 (depends on 33)

The isolated human Growth Hormone protein of claim 33, where said human Growth Hormone protein comprises a cysteine residue substituted for T135.

### Claim 40 (depends on 33)

The isolated human Growth Hormone of claim 33, wherein said isolated Growth Hormone protein is modified with polyethylene glycol.

### Claim 41 (depends on 33)

The isolated human Growth Hormone protein of claim 33, wherein said isolated Growth Hormone protein is modified with a cysteine-reactive polyethylene glycol.

### Claim 42 (depends on 32)

The isolated growth hormone protein dimer of claim 32, where said growth hormone protein dimer is a recombinant protein.

### Claim 43 (depends on 32)

The isolated growth hormone protein dimer of claim 32, wherein the dimer is a homodimer.

### Claim 44

A method for obtaining an isolated, disulfide-linked growth hormone protein dimer comprising two growth hormone protein monomers, wherein each growth hormone protein monomer in the dimer comprises at least one added cysteine residue, and wherein the at least one added cysteine residue participates in a disulfide bond joining the two growth hormone protein monomers together in the dimer, the method comprising:
(a) obtaining a host cell capable of expressing the growth hormone protein comprising at least one added cysteine residue;
(b) causing the host cell to express the growth hormone protein comprising at least one added cysteine residue in a soluble form;
(c) exposing the growth hormone protein comprising at least one added cysteine residue to a cysteine blocking agent prior to step (d); and
(d) isolating the growth hormone protein dimer by column chromatography, wherein the buffers used to elute the growth hormone protein from the column do not contain a cysteine blocking agent.

### Claim 45 (depends on 44)

The method of claim 44, wherein the column chromatography method of step (d) is selected from the group consisting of ion-exchange column chromatography, hydrophobic interaction column chromatography, metal chelation affinity column chromatography, size exclusion column chromatography, and combinations thereof.

### Claim 46 (depends on 44)

The method of claim 44, where the column chromatography method of step (d) is ion-exchange column chromatography.

### Claim 47 (depends on 44)

The method of claim 44, wherein the cysteine blocking agent in step (c) is selected from the group consisting of cystine, oxidized glutathionine, and cystamine.

### Claim 48 (depends on 44)

The method of claim 44, wherein the cysteine blocking agent in step (c) is cystine.

### Claim 49

A method of treating a disease treatable with growth hormone, comprising administering to a patient in need thereof an effective amount of a composition comprising an isolated, disulfide-linked growth hormone protein dimer comprising two growth hormone protein monomers, wherein each growth hormone protein monomer in the dimer comprises at least one added cysteine residue, and wherein the at least one added cysteine residue participates in a disulfide bond joining the two growth hormone protein monomers together in the dimer.

### Claim 50 (depends on 49)

The method of claim 49, wherein the disease is selected from the group consisting of: growth hormone deficiency, short stature resulting from growth hormone deficiency, short stature resulting from Turner's Syndrome, short stature resulting from renal failure, and cachexia.

### Claim 51 (depends on 49)

The method of claim 49, wherein the composition is administered to the patient by a route selected from the group consisting of intravenous administration, intraperitoneal administration, and subcutaneous administration.
